he Centers for Medicare and Medicaid Services (CMS) published the “Specialty Care Models to Improve Quality of Care and Reduce Expenditures (CMS-5527)” final rule.

Getty Images


September 29, 2020 — On Sept. 18, 2020, the Centers for Medicare and Medicaid Services (CMS) published the “Specialty Care Models to Improve Quality of Care and Reduce Expenditures (CMS-5527)” final rule. The final rule includes a mandatory radiation oncology (RO) Model and End-Stage Renal Disease Treatment Choices Model. CMS believes these models will further their goal of shifting away from payment for volume of services alone and toward paying for value and outcomes. The RO Model will qualify as an advanced alternative payment model under the Quality Payment Program.

The RO Model will begin Jan. 1, 2021 and will run through Dec. 31, 2025. Certain radiation therapy (RT) providers and RT suppliers that furnish RT services within randomly selected Core Based Statistical Areas (geographic areas determined by zip code) are required to participate in the RO Model. The RO Model will include 30% of RO episodes in eligible geographic areas. The list of mandatory participants can be found on the RO Model website under “Participating Zip Code List.”

Under the RO Model, Medicare will pay participating providers and suppliers a prospective, site-neutral, episode-based payment for specified technical and professional RT services furnished during a 90-day episode to Medicare fee-for-service beneficiaries diagnosed with 16 different cancer types. An episode will only be triggered if there is an initial treatment planning service and at least one radiation treatment service within 28 days. Furthermore, another episode may not be triggered until at least 28 days after the previous episode has ended, referred to as the “clean period.” The base payment amounts for RT services included in the model will be the same for hospital outpatient departments and freestanding radiation therapy centers.

The American College of Radiology (ACR) will join the American Society for Radiation Oncology (ASTRO) in urging CMS and Congress to significantly delay the start date of the RO Model. Despite recommendations from ASTRO and the ACR to allow providers at least six months from the publication of the final rule to implementation due to the impacts of the COVID-19 public health emergency, CMS’ final rule only allows providers three and a half months to prepare for implementation. On Sept. 18, ASTRO issued a statement calling for additional reforms to the model along with delay in implementation. ASTRO stated that although mandatory participation representing 30% of eligible RO episodes is a positive step from the proposed 40%, this final rule goes too far for an untested model. The ACR strongly supports ASTRO’s statement and will be partnering in advocacy efforts.

Read the ACR initial summary on the model.

Related Radiation Oncology Content:

ASTRO responds to CMS Radiation Oncology Model


Related Content

News | Radiation Therapy

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...

Time February 04, 2026
arrow
News | Radiology Imaging

Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's ...

Time February 04, 2026
arrow
News | Radiopharmaceuticals and Tracers

Jan. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has launched a national program creating Authorized ...

Time January 30, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Radiology Imaging

Jan. 21, 2026 — Cathpax, a spin-off of the Lemer Pax group that designs, develops and commercializes team-wide, full ...

Time January 22, 2026
arrow
News | Radiation Therapy

Jan. 16, 2026 — Elekta has announced that its Elekta Evo* CT-Linac has received 510(k) clearance from the U.S. Food and ...

Time January 16, 2026
arrow
News | Radiopharmaceuticals and Tracers

Dec. 11, 2025 — Telix Pharmaceuticals Ltd. has announced a strategic clinical collaboration with Varian, a Siemens ...

Time December 11, 2025
arrow
News | FDA

Dec. 02, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT, has announced ...

Time December 04, 2025
arrow
News | Interventional Radiology

Nov. 12, 2025 — On Nov. 11, Huntsman Cancer Institute at the University of Utah (the U) opened its first specialized ...

Time November 13, 2025
arrow
News | Radiology Business

Nov. 12, 2025 — Siemens has announced plans to deconsolidate its remaining stake in Siemens Healthineers (currently ...

Time November 13, 2025
arrow
Subscribe Now